A 80-year-old female patient presented with dyspnea intractable to medical therapy. She received surgical mitral valve replacement with Hancock II (Medtronic, Minneapolis, MN, USA) ([Figure 1](#F1){ref-type="fig"}) 27 mm bioprosthetic valve 11 years ago due to severe rheumatic mitral stenosis. Other comorbidities included atrial fibrillation, stroke, and restrictive lung disease. The echocardiography showed a prolapse of bioprosthetic mitral valve posterior leaflet with severe eccentric mitral regurgitation (MR) accompanied by severe resting pulmonary hypertension. The multi-detector computed tomography (MDCT) showed the degenerative change of mitral bioprosthetic valve with posterior leaflet prolapse.

Multi-disciplinary Heart team determined to undergo transcatheter mitral valve-in-valve replacement due to high surgical risk. Based on the MDCT analysis showing 460 mm^2^ of bioprosthetic valve area, we selected the SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) 26 mm transcatheter heart valve with the nominal size (519 mm^2^), which achieved 13% area over-sizing. After the transseptal puncture, the atrial septum was dilated with a 10×40 mm balloon catheter ([Figure 2A](#F2){ref-type="fig"}). A small-curve Safari wire (Boston Scientific, Marlborough, MA, USA) was placed in the left ventricle. The SAPIEN 3 26 mm transcatheter heart valve was delivered into the bioprosthetic mitral valve ([Figure 2B](#F2){ref-type="fig"}) and deployed under rapid ventricular pacing ([Figure 2C](#F2){ref-type="fig"}). Left ventriculogram showed trivial MR without acute complications ([Figure 2D](#F2){ref-type="fig"}). Fluoroscopy showed that about 20% of the prosthesis was placed on the atrial side of the sewing ring ([Figure 3](#F3){ref-type="fig"}). Patient\'s symptoms subsequently improved and echocardiography showed trivial MR with mild resting pulmonary hypertension ([Supplementary Videos 1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"}).

Bioprosthetic mitral valve dysfunction requiring re-operation was about 40% after 15 years following surgical mitral valve replacement.[@B1] Reoperation is considered a high-risk procedure, particularly in elderly patients with multiple comorbidities.[@B2] Transseptal transcatheter mitral valve-in-valve replacement is a promising treatment strategy for those patients with excellent procedural success and acceptable long-term outcomes.[@B3][@B4]
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Video 1

Transthoracic echocardiography after procedure.

###### Supplementary Video 2

Transthoracic echocardiography after procedure without evidence of definite mitral regurgitation.

###### Supplementary Video 3

Transthoracic echocardiography after procedure showing trivial mitral regurgitation.

###### Supplementary Video 4

Final left ventriculography after procedure.

![Hancock II bioprosthetic mitral valve and its fluoroscopic image.](kcj-48-438-g001){#F1}

![(A) Balloon atrial septostomy with 10×40mm balloon. (B) Positioning of Edwards SAPIEN 3 valve within surgical bioprosthesis over a Safari wire. (C) Deployment of SAPIEN 3 valve under rapid ventricular pacing. (D) The left ventriculogram without significant mitral regurgitation after valve deployment.](kcj-48-438-g002){#F2}

![The final fluoroscopic image of mitral valve after the procedure.](kcj-48-438-g003){#F3}
